Investors focused on the Medical space have likely heard of T2 Biosystems (TTOO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
T2 Biosystems is a member of our Medical group, which includes 933 different companies and currently sits at #13 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TTOO is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TTOO's full-year earnings has moved 37.50% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, TTOO has moved about 11.11% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.76%. This means that T2 Biosystems is performing better than its sector in terms of year-to-date returns.
Looking more specifically, TTOO belongs to the Medical - Instruments industry, which includes 95 individual stocks and currently sits at #179 in the Zacks Industry Rank. Stocks in this group have gained about 17.41% so far this year, so TTOO is slightly underperforming its industry this group in terms of year-to-date returns.
TTOO will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of T2 Biosystems (TTOO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
T2 Biosystems is a member of our Medical group, which includes 933 different companies and currently sits at #13 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TTOO is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TTOO's full-year earnings has moved 37.50% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, TTOO has moved about 11.11% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.76%. This means that T2 Biosystems is performing better than its sector in terms of year-to-date returns.
Looking more specifically, TTOO belongs to the Medical - Instruments industry, which includes 95 individual stocks and currently sits at #179 in the Zacks Industry Rank. Stocks in this group have gained about 17.41% so far this year, so TTOO is slightly underperforming its industry this group in terms of year-to-date returns.
TTOO will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TTOO - FREE